PegIFN-α2a for the treatment of chronic hepatitis B and C: A 10-year history

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 5, 2013, Pages 459-474

  Degasperi, Elisabetta ^a   Viganò, Mauro ^a   Aghemo, Alessio ^a   Lampertico, Pietro ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

antiviral therapy; boceprevir; HBV; HCV; nucleos(t)ide analogs; PegIFN 2a; telaprevir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2A INTERFERON; BOCEPREVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; TELBIVUDINE; TENOFOVIR; THYMOSIN ALPHA1;

ANEMIA; ANTIVIRAL ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION; INJECTION SITE REACTION; IRRITABILITY; MOOD CHANGE; MYALGIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84877014011     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.13.37     Document Type: Review

References (112)

1. EASL. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J. Hepatol. 55, 245-264 (2011).
2. EASL. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 57, 167-185 (2012
3. Aghemo A, Lampertico P, Colombo M. Assessing long-Term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. J. Hepatol. 57(6), 1326-1335 (2012
4. D'Ambrosio R, Aghemo A, Rumi MG et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir. Ther. (Lond.) 16(5), 677-684 (2011
5. D'Ambrosio R, Aghemo A, Rumi MG et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56(2), 532-543 (2012
6. Aghemo A, Rumi MG, Colombo M. Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 7(9), 485-494 (2010
7. Aghemo A, Colombo M. Peginterferon α-2B versus peginterferon α-2A with ribavirin for the treatment of chronic hepatitis C: The pursuit of an ideal. Gastroenterology 138(1), 386-389 discussion 389 (2010
8. Prati GM, Aghemo A, Rumi MG et al. Hyporesponsiveness to PegIFNα2b plus ribavirin in patients with hepatitis C-related advanced fibrosis. J. Hepatol. 56(2), 341-347 (2012
9. Platanias LC. Mechanisms of type-I-And type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5(5), 375-386 (2005
10. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436(7053), 967-972 (2005
11. Oliviero B, Mele D, Degasperi E et al. Early NK cell activation predicts successful treatment outcome in chronic HCV infection. Digest. Liver Dis. 43, S86 (2011).
12. Caliceti P. Pharmacokinetics of pegylated interferons: What is misleading? Dig. Liver Dis. 36(Suppl. 3), S334-S339 (2004
13. Aghemo A, Rumi MG, Colombo M. Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C. Expert Rev. Anti. Infect. Ther. 7(8), 925-935 (2009
14. Harris JM, Martin NE, Modi M. Pegylation: A novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40(7), 539-551 (2001
15. Bailon P, Palleroni A, Schaffer CA et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug. Chem. 12(2), 195-202 (2001
16. Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon α-2a (40 kD). Semin. Liver Dis. 24(SuPPL 2), 33-38 (2004
17. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45(2), 507-539 (2007
18. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int. 25(3), 472-489 (2005
19. Lampertico P, Del Ninno E, Viganò M et al. Long-Term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 37(4), 756-763 (2003
20. Oliveri F, Puoti M, Santantonio T et al. Efficacy and impact on disease progression of IFN treatment in patients with HBeAg-negative chronic hepatitis B: A long term Italian multicenter A.I.S.F. cohort study. Hepatology 42, 577A (2005
21. Fattovich G. Natural history and prognosis of hepatitis B. Semin. Liver Dis. 23(1), 47-58 (2003
22. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J. Hepatol. 48(2), 335-352 (2008
23. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. 24(Suppl 1), 17-21 (2004
24. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-Term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. 34(2), 306-313 (2001
25. Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in α-interferon treated and untreated patients: A long term cohort study. J. epatol. 36(2), 263-270 (2002
26. Di Marco V, Lo Iacono O, Cammà C et al. The long-Term course of chronic hepatitis B. Hepatology 30(1), 257-264 (1999
27. Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon α-2a (40 kDa): An advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B. J. Viral Hepat. 10(4), 298-305 (2003
28. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352(26), 2682-2695 (2005
29. Piratvisuth T, Lau G, Chao YC et al. Sustained response to peginterferon α-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol. Int. 2(1), 102-110 (2008
30. Liaw YF, Jia JD, Chan HL et al. Shorter durations and lower doses of peginterferon α-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 54(5), 1591-1599 (2011
31. Wang YD, Zhao CY, Wang W et al. Improved efficacy by individualized combination therapy with Peg IFN-α 2a and ADV in HBeAg positive chronic hepatitis B patients. Hepatogastroenterology 59(115), 680-686 (2012
32. Kim BH, Lee YJ, Kim W et al. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. Scand J. Gastroenterol. 8-9(47), 1048-1055 (2012
33. Marcellin P, Avila C, Wursthorn K et al. Telbivudine (LdT) plus peg-interferon (Peg-IFN) in HBeAg-positive chronic hepatitis B -very potent antiviral efficacy but risk of peripheral neuropathy (PN J. Hepatol. 51, S6-S7 (2010
34. Hui CK, Lai LS, Lam P et al.; Hong Kong Liver Fibrosis Study Group. 48 weeks pegylated interferon α-2a is superior to 24 weeks of pegylated interferon α-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection. Aliment. Pharmacol. Ther. 23(8), 1171-1178 (2006
35. Sun J, Hou JL, Xie Q et al. Randomised clinical trial: Efficacy of peginterferon α-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment. Pharmacol. Ther. 34(4), 424-431 (2011
36. Marcellin P, Lau GK, Bonino F et al. rffrt Peginterferon α-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351(12), 1206-1217 (2004
37. Bonino F, Marcellin P, Lau GK et al. Peginterferon α-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56(5), 699-705 (2007
38. Marcellin P, Piratvisuth T, Brunetto M et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon α-2a ± lamivudine: Results of 5-year post treatment follow up. J. Hepatol. 50, S336 (2009
39. Piccolo P, Lenci I, Demelia L et al. A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir. Ther. (Lond.) 14(8), 1165-1174 (2009
40. Moucari R, Boyer N, Ripault MP et al. Sequential therapy with adefovir dipivoxil and pegylated interferon α-2a for HBeAg-negative patients. J. Viral Hepat. 18(8), 580-586 (2011
41. Rijckborst V, ter Borg MJ, Cakaloglu Y et al.; PARC Study Group. A randomized trial of peginterferon α-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am. J. Gastroenterol. 105(8), 1762-1769 (2010
42. Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon α-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am. J. Gastroenterol. 102(12), 2718-2723 (2007
43. Lampertico P, Viganò M, Di Costanzo GG et al. A randomized study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 62(2), 290-298 (2013
44. Chow WC, Manns M, Paik SW et al. Effect of ethnicity, genotype, gender, age and body weight on sustained response in a large, randomised study of peginterferon -2a (40 KD) (PEGASYSs) ± lamivudine versus lamivudine alone for HBeAg-positive chronic hepatitis B. Hepatology 42, 576A (2005
45. Fried MW, Piratvisuth T, Lau GK et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon α-2a for HBeAg-positive chronic hepatitis B. Hepatology 47(2), 428-434 (2008
46. Wong VW, Wong GL, Yan KK et al. Durability of peginterferon α-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51(6), 1945-1953 (2010
47. Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: Association with sustained response to peginterferon α-2a in hepatitis B e antigen-positive patients. Hepatol. Int. doi:10.1002/hep.22760 (2011 (Epub ahead of print
48. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon α-2b for hepatitis B e antigen-positive chronic hepatitis B using on-Treatment hepatitis B surface antigen decline. Hepatology 52(4), 1251-1257 (2010
49. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology 53(3), 1054-1055
50. Sonneveld MJ, Hansen BE, Piratvisuth T et al. Response-guided peginterferon therapy in HBeAg-positive chronic hepatitis B using serum hepatitis B surface antigen levels: A pooled analysis of 803 patients. Hepatology 56, 202A (2012
51. Moucari R, Mackiewicz V, Lada O et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon α-2a in HBeAgnegative patients. Hepatology 49(4), 1151-1157 (2009
52. Marcellin P, Piratvisuth T, Brunetto M et al. On-Treatment decline in serum HBsAg levels predicts sustained immune control 1 year posttreatment, subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon α-2a. Hepatol. Int. 4, 151 (2010
53. Marcellin P, Brunetto M, Bonino F et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years posttreatment. Hepatology 48, 718A (2008
54. Brunetto MR, Moriconi F, Bonino F et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon α-2a in HBeAg-negative chronic hepatitis B. Hepatology 49(4), 1141-1150 (2009
55. Rijckborst V, Hansen BE, Cakaloglu Y et al. Early on-Treatment prediction of response to peginterferon α-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52(2), 454-461 (2010
56. Rijckborst V, Hansen BE, Ferenci P et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon α-2a. J. Hepatol. 56(5), 1006-1011 (2012
57. Tseng TC, Yu ML, Liu CJ et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. Antivir. Ther. (Lond.) 16(5), 629-637 (2011
58. Sonneveld MJ, Wong VW, Woltman AM et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 142(3), 513-520.e1 (2012
59. Wu X, Xin Z, Zhu X et al. Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese. Antiviral Res. 93(2), 297-300 (2012
60. Lampertico P, Viganò M, Cheroni C et al. IL28B polymorphisms predict interferonrelated hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 57(3), 890-896 (2013
61. Lampertico P, Galmozzi E, Colombo M. Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype. Hepatology doi:10.1002/hep.25882 (2012) (Epub ahead of print
62. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33(2), 433-438 (2001
63. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002
64. Hadziyannis SJ, Sette H Jr, Morgan TR et al.; PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346-355 (2004).
65. Reddy KR, Shiffman ML, Rodriguez-Torres M et al.; PROGRESS Study Investigators. Induction pegylated interferon α-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 139(6), 1972-1983 (2010
66. Roberts SK, Weltman MD, Crawford DH et al.; Chariot Study Group. Impact of high-dose peginterferon α-2a on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. Hepatology 50(4), 1045-1055 (2009
67. Rotman Y, Borg BB, Soza A et al. Low-And standard-dose peginterferon α-2a for chronic hepatitis C, genotype 2 or 3: Efficacy, tolerability, viral kinetics and cytokine response. Aliment. Pharmacol. Ther. 31(9), 1018-1027 (2010
68. Ferenci P, Brunner H, Laferl H et al. Austrian Hepatitis Study Group. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon α-2a in hepatitis C virus genotypes 2 and 3. Hepatology 47(6), 1816-1823 (2008
69. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon α-2a (40 KD)/ribavirin. J. Hepatol. 43(3), 425-433 (2005
70. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology 43(5), 954-960 (2006
71. Zeuzem S, Pawlotsky JM, Lukasiewicz E et al.; DITTO-HCV Study Group. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J. Hepatol. 43(2), 250-257 (2005
72. von Wagner M, Huber M, Berg T et al. Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129(2), 522-527 (2005
73. Shiffman ML, Suter F, Bacon BR et al. ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357(2), 124-134 (2007).
74. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-α- 2a plus ribavirin. Gastroenterology 130(4), 1086-1097 (2006
75. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferonα- plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 44(1), 97-103 (2006
76. Asselah T, Estrabaud E, Bieche I et al. Hepatitis C: Viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 30(9), 1259-1269 (2010
77. Romero-Gómez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128(3), 636-641 (2005
78. Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon α-2a (40KD) and ribavirin. Scand. J. Gastroenterol. 42(2), 247-255 (2007
79. Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139(1), 120.e18-129.e18 (2010
80. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132(5), 1767-1777 (2007
81. Kieffer TL, Sarrazin C, Miller JS et al. Telaprevir and pegylated interferon-Alpha- inhibit wild-Type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46(3), 631-639 (2007
82. McHutchison JG, Everson GT, Gordon SC et al.; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360(18), 1827-1838 (2009
83. Hézode C, Forestier N, Dusheiko G et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360(18), 1839-1850 (2009
84. McHutchison JG, Manns MP, Muir AJ et al.; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362(14), 1292-1303 (2010
85. Kwo PY, Lawitz EJ, McCone J et al. SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon α-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre Phase 2 trial. Lancet 376(9742), 705-716 (2010
86. Jacobson IM, McHutchison JG, Dusheiko G et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405-2416 (2011
87. Sherman KE, Flamm SL, Afdhal NH et al. ILLUMINATE Study Team. Responseguided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365(11), 1014-1024 (2011
88. Poordad F, McCone J Jr, Bacon BR et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195-1206 (2011
89. Bacon BR, Gordon SC, Lawitz E et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1207-1217 (2011
90. Flamm S, Lawitz I, Jacobson R et al. High sustained virologic response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-Treated with boceprevir (BOC) plus peginterfeon alfa-2a/ribavirin. J. Hepatol. 54S, 541-542 (2012
91. Janssen HL, van Zonneveld M, Senturk H et al.; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 365(9454), 123-129 (2005
92. van Zonneveld M, Flink HJ, Verhey E et al.; HBV 99-01 Study Group. The safety of pegylated interferon α-2b in the treatment of chronic hepatitis B: Predictive factors for dose reduction and treatment discontinuation. Aliment. Pharmacol. Ther. 21(9), 1163-1171 (2005
93. Marcellin P, Lau GK, Zeuzem S et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with eginterferon α-2a. Liver Int. 28(4), 477-485 (2008
94. Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int. 33(Suppl 1), 111-115 (2013
95. Cardoso AC, Moucari R, Figueiredo-Mendes C et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J. Hepatol. 52(5), 652-657 (2010
96. Aghemo A, Prati GM, Rumi MG et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 56(5), 1681-1687 (2012
97. Viganò M, Aghemo A, Iavarone M et al. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. Antivir. Ther. (Lond.) 14(6), 789-796 (2009
98. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Analysis of the efficacy of treatment with peginterferon α-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int. 29(10), 1485-1493 (2009
99. Liu CJ, Chuang WL, Lee CM et al. Peginterferon α-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136(2), 496-504.e3 (2009
100. Yu ML, Lee CM, Chen CL et al.; Taiwan Liver-Net Consortium. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-Treatment follow-up. Hepatology doi:10.1002/hep.26266 (2013 (Epub ahead of print
101. Sonneveld MJ, Xie Q, Zhang NP et al. Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance -first results from a global randomized trial (ARES study). Hepatology 56S1, 199A (2012
102. Marcellin P, Martinot-Peignoux M, Martine L et al. High rates of HBsAg loss predicted by baseline HBsAg titer and decline on treatment in chronic hepatitis B patients receiving pegylated interferon plus tenofovir combination therapy. Hepatology 54, 1010A (2011
103. Kittner JM, Sprinzl MF, Grambihler A et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J. Clin. Virol. 54(1), 93-95 (2012).
104. Ouzan D, Penaranda G, Joly H et al. Add-on of Peg interferon to a stable nucleoside regimen led to loss of HBsAg in chronic hepatitis HBeAg-negative patients. Hepatology 54, 1015A (2011
105. Lampertico P, Invernizzi F, Soffredini R et al. Add-on Peg-IFN improves HBsAg kinetics in patients long-Term fully suppressed by nucleos(t)ide analogs. J. Hepatol. 56S2, S207 (2012
106. Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: A drug caught between past and future. Expert Opin. Biol. Ther. 11(3), 301-313 (2011
107. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6), 1887-1898 (2006
108. Zeuzem S, Arora B, Bacon T et al. Peginterferon λ-1a compared to peginterferon α-2a in treatment-naive patients with HCV genotypes 2 or 3: First SVR24 results from emerge Phase IIB. J. Hepatol. 56, S5-S6 (2012
109. Gane EJ, Roberts SK, Stedman CA et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467-1475 (2010
110. Chayama K, Takahashi S, Toyota J et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55, 742-748 (2012
111. Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216-224 (2012
112. Karabay O, Tuna N, Esen S; PEG-HBV Study Group. Comparative efficacy of pegylated interferons α-2a and 2b in the treatment of HBeAg-negative chronic hepatitis B infection. Eur. J. Gastroenterol. Hepatol. 24(11), 1296-1301 (2012